Solution for Intravenous Infusion
Professed Standard Therapeutic Classification: Antineoplastic
BAVENCIO has been issued marketing authorization with conditions for the treatment of:
These indications are pending the results of studies to verify its clinical benefit. Patients should be advised of the nature of the authorization. For further information for BAVENCIO please refer to Health Canada’s Notice of Compliance with conditions - drug products web site: http://www.hc-sc.gc.ca/dhp-mps/prodpharma/notices-avis/conditions/index-eng.php.
BAVENCIO has been issued marketing authorization without conditions for: